genetic heart diseases
“If you're going to try to embrace new worlds, you must try to embrace new ideas."
genetic heart diseases
genetic heart diseases
genetic heart diseases
SEO related. Do not remove this box.
Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Imagine the possibilities of our approach. We envision a world where our technology can cure genetic heart diseases, providing lifelong benefit to patients and their relatives.
Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines.
Latest News
Phlox Therapeutics Secures New Funding to Advance RNA Therapies for Genetic Cardiomyopathies
Phlox Therapeutics raises 1.9M funding to develop RNA therapies for genetic laminopathies The investor syndicate includes ROM Utrecht Region, FIRST Fund, Amsterdam-UMC Ventures and UHSF Funds support preclinical development of Phox’s lead program Naarden, The Netherlands, 6 November 2024 – Phlox Therapeutics (“Phlox”), a private biotechnology company focused on developing innovative RNA-based therapies for cardiomyopathies, […]
Phlox Therapeutics Raises Additional Seed Funding to Further Develop RNA Therapies for Genetic Laminopathies
Phlox Therapeutics raises additional seed funding to develop RNA therapies for genetic laminopathies Funds will advance the company’s lead program into preclinical development 9 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead […]
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases Research collaboration to target severe form of genetic dilated […]
“If you're going to try to embrace new worlds, you must try to embrace new ideas."
Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Imagine the possibilities of our approach. We envision a world where our technology can cure genetic heart diseases, providing lifelong benefit to patients and their relatives.
Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines.
Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines.
Latest news
Phlox Therapeutics Secures New Funding to Advance RNA Therapies for Genetic Cardiomyopathies
Phlox Therapeutics raises 1.9M funding to develop RNA therapies for genetic laminopathies The investor syndicate includes ROM Utrecht Region, FIRST Fund, Amsterdam-UMC Ventures and UHSF Funds support preclinical development of Phox’s lead program Naarden, The Netherlands, 6 November 2024 – Phlox Therapeutics (“Phlox”), a private biotechnology company focused on developing innovative RNA-based therapies for cardiomyopathies, […]
Phlox Therapeutics Raises Additional Seed Funding to Further Develop RNA Therapies for Genetic Laminopathies
Phlox Therapeutics raises additional seed funding to develop RNA therapies for genetic laminopathies Funds will advance the company’s lead program into preclinical development 9 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead […]
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases Research collaboration to target severe form of genetic dilated […]